Suzhou CreMed Biomedical Technology

CreMed Biomedical is a clinical-stage biotechnology company specializing in the development of long-acting ophthalmic therapies to treat chronic eye diseases. Based in Suzhou, China, the company utilizes proprietary microsphere and hydrogel-based drug delivery platforms to extend the therapeutic effect of both biologics and small molecules. Their primary focus is addressing the high treatment burden of frequent intravitreal injections for conditions like wet age-related macular degeneration and diabetic macular edema. The lead program, CRM-001, is a sustained-release VEGF inhibitor designed to provide multi-month efficacy from a single dose. CreMed's pipeline also extends to long-acting treatments for glaucoma and other retinal vascular disorders. By combining advanced formulation science with clinical expertise, the company aims to significantly improve patient compliance and visual outcomes.